debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC

August 2000

There's lots of debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC.

The FDA is holding meetings...and considering it for the U.S. Canadian officials are watching this closely.

Several medical and pharmacy associations strongly support it.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC
Cholesterol updated guidelines for treating high cholesterol
Cholesterol Lipidil Supra, a new formulation of fenofibrate
new ways to relieve hot flashes
new guidelines for treating PMS
Sarafem, a new version of fluoxetine
Insomnia herbal products for sleep
Diabetes New One Touch FastTake test strips will allow patients to use a blood sample from their ARM
Diabetes more aggressive treatment of hypertension in patients with diabetes
Gastroenterology concern about serious GI side effects with Lotronex
Osteoporosis statins to reduce the risk of osteoporosis
Osteoporosis don't realize they still need calcium and vitamin D
Osteoporosis Fosamax (alendronate) just ONCE A WEEK
Cardiology new once-daily beta-blocker for hypertension called Monocor (bisoprolol)
Pregnancy which psychotropics they can give to women during pregnancy
Infectious Diseases antibiotics to treat certain strains of E. coli INCREASES the risk of complications